AU2018211561B2 - Calicheamicin derivatives and antibody drug conjugates thereof - Google Patents
Calicheamicin derivatives and antibody drug conjugates thereof Download PDFInfo
- Publication number
- AU2018211561B2 AU2018211561B2 AU2018211561A AU2018211561A AU2018211561B2 AU 2018211561 B2 AU2018211561 B2 AU 2018211561B2 AU 2018211561 A AU2018211561 A AU 2018211561A AU 2018211561 A AU2018211561 A AU 2018211561A AU 2018211561 B2 AU2018211561 B2 AU 2018211561B2
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- optionally substituted
- group
- c4alkyl
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 CC([C@](CCCCN*)NC(C)=O)=O Chemical compound CC([C@](CCCCN*)NC(C)=O)=O 0.000 description 23
- HFNGYHHRRMSKEU-UHFFFAOYSA-N CC(OCc(cc1)ccc1OC)=O Chemical compound CC(OCc(cc1)ccc1OC)=O HFNGYHHRRMSKEU-UHFFFAOYSA-N 0.000 description 4
- FEGKEUODYZVQRY-UHFFFAOYSA-N CC(OCc(cc1)ccc1NC)=O Chemical compound CC(OCc(cc1)ccc1NC)=O FEGKEUODYZVQRY-UHFFFAOYSA-N 0.000 description 3
- QOSCCSMYIRPMAB-JTQLQIEISA-N CCCCC[C@@H](C(C)=O)NC(C)=O Chemical compound CCCCC[C@@H](C(C)=O)NC(C)=O QOSCCSMYIRPMAB-JTQLQIEISA-N 0.000 description 2
- JOJNHKAQBKZPJA-UHFFFAOYSA-N CNc1ccc(COC)cc1 Chemical compound CNc1ccc(COC)cc1 JOJNHKAQBKZPJA-UHFFFAOYSA-N 0.000 description 2
- UBFYKIAACUWHLL-XMBAFOPISA-N C[C@@H]([C@@H]([C@H]([C@H]1O)OC)O)O[C@H]1Oc(c(I)c(C)c(C(S[C@H]([C@@H](C)O[C@H](C1)OC)[C@H]1O)=O)c1OC)c1OC Chemical compound C[C@@H]([C@@H]([C@H]([C@H]1O)OC)O)O[C@H]1Oc(c(I)c(C)c(C(S[C@H]([C@@H](C)O[C@H](C1)OC)[C@H]1O)=O)c1OC)c1OC UBFYKIAACUWHLL-XMBAFOPISA-N 0.000 description 2
- YXBCSJMDYNTZCY-PDHYLSHYSA-N CC(C)(C)CCNC(OCc(cc1)ccc1OC([C@@H]([C@H]([C@@H]1O)O)O)O[C@@H]1C(O)=O)=O Chemical compound CC(C)(C)CCNC(OCc(cc1)ccc1OC([C@@H]([C@H]([C@@H]1O)O)O)O[C@@H]1C(O)=O)=O YXBCSJMDYNTZCY-PDHYLSHYSA-N 0.000 description 1
- VGUPVUJMQIBKPG-UHFFFAOYSA-N CC(C)(CC(Cl)=O)SS Chemical compound CC(C)(CC(Cl)=O)SS VGUPVUJMQIBKPG-UHFFFAOYSA-N 0.000 description 1
- BGIKBGVCTGOSTR-RYUDHWBXSA-N CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(C)=O)=O)NC(C)=O Chemical compound CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(C)=O)=O)NC(C)=O BGIKBGVCTGOSTR-RYUDHWBXSA-N 0.000 description 1
- SMPKIGVZMCFGSV-UHFFFAOYSA-N CC(NC(C)=C)I Chemical compound CC(NC(C)=C)I SMPKIGVZMCFGSV-UHFFFAOYSA-N 0.000 description 1
- SIFCHNIAAPMMKG-UHFFFAOYSA-N CC(ON(C(CC1)=O)C1=O)=O Chemical compound CC(ON(C(CC1)=O)C1=O)=O SIFCHNIAAPMMKG-UHFFFAOYSA-N 0.000 description 1
- ZEOUKNRGJKUKTH-SECBINFHSA-N CC([C@@H](CCCCN)NC(C)=O)=O Chemical compound CC([C@@H](CCCCN)NC(C)=O)=O ZEOUKNRGJKUKTH-SECBINFHSA-N 0.000 description 1
- UCSODWHXBVIXQR-BQYQJAHWSA-N CCCC/C=C/C(C(C)=O)NC(C)=O Chemical compound CCCC/C=C/C(C(C)=O)NC(C)=O UCSODWHXBVIXQR-BQYQJAHWSA-N 0.000 description 1
- QOSCCSMYIRPMAB-SNVBAGLBSA-N CCCCC[C@H](C(C)=O)NC(C)=O Chemical compound CCCCC[C@H](C(C)=O)NC(C)=O QOSCCSMYIRPMAB-SNVBAGLBSA-N 0.000 description 1
- BNFKONHSHNMIIP-BNGQLXBHSA-N CCN[C@@H](CO[C@H](C1)O[C@H]([C@H]2O)[C@H](O[C@H](C(/C(/[C@](C)(CC3=O)O)=C\CSS[C@H](C)COC(Nc(cc4)cc(O5)c4C(C)=CC5=O)=O)=C3NC(C=O)=O)C#C/C=C\C)O[C@H](C)C2/C=N\O[C@@H](C[C@@H]2O)O[C@H](C)[C@H]2SC(c(c(OC)c2OC)c(C)c(I)c2O[C@@H]([C@@H]([C@@H]2OC)O)O[C@@H](C)[C@@H]2O)=O)[C@H]1OC Chemical compound CCN[C@@H](CO[C@H](C1)O[C@H]([C@H]2O)[C@H](O[C@H](C(/C(/[C@](C)(CC3=O)O)=C\CSS[C@H](C)COC(Nc(cc4)cc(O5)c4C(C)=CC5=O)=O)=C3NC(C=O)=O)C#C/C=C\C)O[C@H](C)C2/C=N\O[C@@H](C[C@@H]2O)O[C@H](C)[C@H]2SC(c(c(OC)c2OC)c(C)c(I)c2O[C@@H]([C@@H]([C@@H]2OC)O)O[C@@H](C)[C@@H]2O)=O)[C@H]1OC BNFKONHSHNMIIP-BNGQLXBHSA-N 0.000 description 1
- BMKDCKYHJLAZKR-ULFNDUEJSA-N CC[C@H](C(C([C@H]1O)=C)=O)OC1I Chemical compound CC[C@H](C(C([C@H]1O)=C)=O)OC1I BMKDCKYHJLAZKR-ULFNDUEJSA-N 0.000 description 1
- JDLNDPNODBOVKB-RZKWMIHSSA-N CC[IH][C@H](CC1)CO[C@H]1O[C@H]1[C@H](O[C@H](C(/C(/[C@@](CC2=O)(N)O)=C\CSSC(C)C)=C2NC(OC)=O)C#C/C=C\C)O[C@H](C)C[C@@H]1O Chemical compound CC[IH][C@H](CC1)CO[C@H]1O[C@H]1[C@H](O[C@H](C(/C(/[C@@](CC2=O)(N)O)=C\CSSC(C)C)=C2NC(OC)=O)C#C/C=C\C)O[C@H](C)C[C@@H]1O JDLNDPNODBOVKB-RZKWMIHSSA-N 0.000 description 1
- YKRXGMOJRVFUAV-ROFBASKPSA-N C[C@@H]([C@@H](C[C@H]1O)O)O[C@H]1Oc(c(I)c(C)c(C(S[C@H]([C@@H](C)O[C@H](C1)ON)[C@H]1O)=O)c1OC)c1OC Chemical compound C[C@@H]([C@@H](C[C@H]1O)O)O[C@H]1Oc(c(I)c(C)c(C(S[C@H]([C@@H](C)O[C@H](C1)ON)[C@H]1O)=O)c1OC)c1OC YKRXGMOJRVFUAV-ROFBASKPSA-N 0.000 description 1
- BYOYXETZZXCIDF-QLTSTAOESA-N C[C@@H]([C@@H]([C@H]([C@H]1O)OC)O)O[C@H]1Oc(c(I)c(C)c(C(S[C@H]([C@@H](C)O[C@H](C1)ON)[C@H]1O)=O)c1OC)c1OC Chemical compound C[C@@H]([C@@H]([C@H]([C@H]1O)OC)O)O[C@H]1Oc(c(I)c(C)c(C(S[C@H]([C@@H](C)O[C@H](C1)ON)[C@H]1O)=O)c1OC)c1OC BYOYXETZZXCIDF-QLTSTAOESA-N 0.000 description 1
- SJHAMFJFHDSHIH-VCQFTWBDSA-N C[C@@H]([C@H](C)O[C@@H](C)[C@@H]1O)[C@H]1OC Chemical compound C[C@@H]([C@H](C)O[C@@H](C)[C@@H]1O)[C@H]1OC SJHAMFJFHDSHIH-VCQFTWBDSA-N 0.000 description 1
- DEWMSYHIQRGITF-UHFFFAOYSA-N Nc(c(N)c(c(OC(Oc(c(N)c(c(N)c1N)N)c1N)=O)c1N)N)c1N Chemical compound Nc(c(N)c(c(OC(Oc(c(N)c(c(N)c1N)N)c1N)=O)c1N)N)c1N DEWMSYHIQRGITF-UHFFFAOYSA-N 0.000 description 1
- YNLUOXLGFYRYJB-SRLRNVHISA-N OC(C([C@H](C1O)O)OC[C@@H]1O)O Chemical compound OC(C([C@H](C1O)O)OC[C@@H]1O)O YNLUOXLGFYRYJB-SRLRNVHISA-N 0.000 description 1
- JXRGUPLJCCDGKG-UHFFFAOYSA-N [O-][N+](c(cc1)ccc1S(Cl)(=O)=O)=O Chemical compound [O-][N+](c(cc1)ccc1S(Cl)(=O)=O)=O JXRGUPLJCCDGKG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762449839P | 2017-01-24 | 2017-01-24 | |
| US62/449,839 | 2017-01-24 | ||
| PCT/IB2018/050153 WO2018138591A1 (en) | 2017-01-24 | 2018-01-10 | Calicheamicin derivatives and antibody drug conjugates thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2018211561A1 AU2018211561A1 (en) | 2019-07-18 |
| AU2018211561B2 true AU2018211561B2 (en) | 2020-04-30 |
Family
ID=61168135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018211561A Ceased AU2018211561B2 (en) | 2017-01-24 | 2018-01-10 | Calicheamicin derivatives and antibody drug conjugates thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11993625B2 (https=) |
| EP (1) | EP3573995A1 (https=) |
| JP (1) | JP7078405B2 (https=) |
| KR (1) | KR20190111086A (https=) |
| CN (1) | CN110461860A (https=) |
| AU (1) | AU2018211561B2 (https=) |
| BR (1) | BR112019015069A2 (https=) |
| CA (1) | CA3051038C (https=) |
| IL (1) | IL268245A (https=) |
| MX (1) | MX2019008773A (https=) |
| RU (1) | RU2732568C1 (https=) |
| SG (1) | SG11201906414VA (https=) |
| TW (1) | TWI687221B (https=) |
| WO (1) | WO2018138591A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| WO2018138591A1 (en) * | 2017-01-24 | 2018-08-02 | Pfizer Inc. | Calicheamicin derivatives and antibody drug conjugates thereof |
| EP3720504A1 (en) | 2017-12-06 | 2020-10-14 | Synaffix B.V. | Enediyne conjugates |
| EP3976112A1 (en) * | 2019-06-03 | 2022-04-06 | Synaffix B.V. | Acetal-based cleavable linkers |
| GB2585102B (en) | 2019-10-09 | 2021-06-30 | Audio Inventions Ltd | System for identification of a note played by a musical instrument |
| WO2025151608A1 (en) * | 2024-01-10 | 2025-07-17 | Systimmune, Inc. | Connecting units for ligand-drug conjugates and methods of making and using thereof |
| WO2026050757A2 (en) * | 2024-08-30 | 2026-03-05 | ALX Oncology Inc. | Calicheamicin derivatives and antibody-drug conjugates thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5606040A (en) * | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| WO2017172907A1 (en) * | 2016-03-29 | 2017-10-05 | Sorrento Therapeutics, Inc. | Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2036891B (en) | 1978-12-05 | 1983-05-05 | Windsor Smith C | Change speed gear |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
| ATE112172T1 (de) | 1987-10-30 | 1994-10-15 | American Cyanamid Co | Targetformer von antitumor-methyltrithioagenzien. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
| WO2005009882A1 (en) * | 2003-06-27 | 2005-02-03 | Otis Elevator Company | Absolute positioning system for elevators using dual encoders |
| DK3248613T3 (da) | 2005-07-18 | 2022-03-14 | Seagen Inc | Beta-glucuronid-lægemiddel-linkerkonjugater |
| EP1886696A1 (en) * | 2006-08-03 | 2008-02-13 | Endotis Pharma | Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| BR112012031727B1 (pt) * | 2010-06-15 | 2022-03-29 | Genmab A/S | Conjugado de droga-anticorpo, composição farmacêutica, e, uso do conjugado de droga- anticorpo |
| RU2012157167A (ru) | 2010-07-12 | 2014-08-20 | КовЭкс Текнолоджиз Айэлэнд Лимитед | Полифункциональные антительные конъюгаты |
| CA2813411C (en) | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| TWI495644B (zh) | 2011-11-11 | 2015-08-11 | Rinat Neuroscience Corp | 營養層細胞表面抗原（Ｔｒｏｐ－２）之專一性抗體類及彼等之用途 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| JP2015502397A (ja) | 2011-12-23 | 2015-01-22 | ファイザー・インク | 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用 |
| CN105121421B (zh) | 2012-11-05 | 2020-10-02 | 辉瑞公司 | 司普力西欧他汀类似物 |
| US9453508B2 (en) | 2013-02-25 | 2016-09-27 | Asmo Co., Ltd. | Electric oil pump and hydraulic pressure supply device |
| KR101614151B1 (ko) | 2014-07-01 | 2016-04-22 | 한국화학연구원 | 흡입 독성 시험용 폐 모델 장치 |
| PL3185908T3 (pl) | 2014-08-28 | 2020-09-07 | Pfizer Inc. | Łączniki modulujące stabilność do stosowania z koniugatami przeciwciało-lek |
| EP3365025B1 (en) * | 2015-10-20 | 2020-07-15 | Genentech, Inc. | Calicheamicin-antibody-drug conjugates and methods of use |
| WO2018069851A2 (en) * | 2016-10-11 | 2018-04-19 | Sorrento Therapeutics, Inc. | C-met antibody drug conjugate |
| WO2018138591A1 (en) * | 2017-01-24 | 2018-08-02 | Pfizer Inc. | Calicheamicin derivatives and antibody drug conjugates thereof |
-
2018
- 2018-01-10 WO PCT/IB2018/050153 patent/WO2018138591A1/en not_active Ceased
- 2018-01-10 RU RU2019123161A patent/RU2732568C1/ru active
- 2018-01-10 MX MX2019008773A patent/MX2019008773A/es unknown
- 2018-01-10 BR BR112019015069-2A patent/BR112019015069A2/pt not_active Application Discontinuation
- 2018-01-10 SG SG11201906414VA patent/SG11201906414VA/en unknown
- 2018-01-10 EP EP18703623.1A patent/EP3573995A1/en active Pending
- 2018-01-10 AU AU2018211561A patent/AU2018211561B2/en not_active Ceased
- 2018-01-10 CN CN201880020707.5A patent/CN110461860A/zh active Pending
- 2018-01-10 US US16/477,290 patent/US11993625B2/en active Active
- 2018-01-10 KR KR1020197024719A patent/KR20190111086A/ko not_active Withdrawn
- 2018-01-10 CA CA3051038A patent/CA3051038C/en active Active
- 2018-01-22 JP JP2018008065A patent/JP7078405B2/ja active Active
- 2018-01-23 TW TW107102314A patent/TWI687221B/zh not_active IP Right Cessation
-
2019
- 2019-07-24 IL IL268245A patent/IL268245A/en unknown
-
2024
- 2024-04-05 US US18/627,949 patent/US20240409573A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5606040A (en) * | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| WO2017172907A1 (en) * | 2016-03-29 | 2017-10-05 | Sorrento Therapeutics, Inc. | Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin |
Non-Patent Citations (2)
| Title |
|---|
| CHARLES E. MELANÇON ET AL, "Glyco-Stripping and Glyco-Swapping", ACS CHEMICAL BIOLOGY, US, 2006, vol. 1, no. 8, pages 499 - 504, doi:10.1021/cb600365 * |
| HINMAN L M ET AL, "PREPARATION AND CHARACTERIZATION OF MONOCLONAL ANTIBODY CONJUGATES OF THE CALICHEAMICINS: A NOVEL AND POTENT FAMILY OF ANTITUMOR ANTIBIOTICS", CANCER RESEARCH, AACR, 1993, vol. 53, no. 14, pages 3336 - 3342 * |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2732568C1 (ru) | 2020-09-21 |
| WO2018138591A1 (en) | 2018-08-02 |
| EP3573995A1 (en) | 2019-12-04 |
| CN110461860A (zh) | 2019-11-15 |
| IL268245A (en) | 2019-09-26 |
| JP2018123122A (ja) | 2018-08-09 |
| JP7078405B2 (ja) | 2022-05-31 |
| BR112019015069A2 (pt) | 2020-03-03 |
| TW201838632A (zh) | 2018-11-01 |
| AU2018211561A1 (en) | 2019-07-18 |
| MX2019008773A (es) | 2019-09-18 |
| KR20190111086A (ko) | 2019-10-01 |
| CA3051038A1 (en) | 2018-08-02 |
| SG11201906414VA (en) | 2019-08-27 |
| US20190345186A1 (en) | 2019-11-14 |
| TWI687221B (zh) | 2020-03-11 |
| CA3051038C (en) | 2022-07-26 |
| US20240409573A1 (en) | 2024-12-12 |
| US11993625B2 (en) | 2024-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018211561B2 (en) | Calicheamicin derivatives and antibody drug conjugates thereof | |
| CA2852860C (en) | Cytotoxic peptides and antibody drug conjugates thereof | |
| DK2917195T5 (en) | SPLICEOSTATINAL ANALOGES | |
| WO2014151030A1 (en) | Cell proliferation inhibitors and conjugates thereof | |
| CN106573956A (zh) | 澳瑞他汀衍生物及其缀合物 | |
| US20170326250A1 (en) | Cell proliferation inhibitors and conjugates thereof | |
| CN119095625A (zh) | 抗体-药物偶联物 | |
| JP2019507126A (ja) | ツブリシン類似体およびこれらの調製のための方法 | |
| CN119156232A (zh) | 抗体-药物偶联物前体及其合成中间体 | |
| CN107660208B (zh) | 包含cti药效团的双功能细胞毒性剂 | |
| HK40017839A (en) | Calicheamicin derivatives and antibody drug conjugates thereof | |
| AU2015264844B2 (en) | Cytotoxic peptides and antibody drug conjugates thereof | |
| WO2025139993A1 (zh) | 一类抗体药物偶联物、其药物组合物及应用 | |
| HK1245252B (zh) | 包含cti药效团的双功能细胞毒性剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |